UNDERSTANDING NEUROPATHY
IN THE PHASE III ABRAXANE TRIAL

48% of patients who received ABRAXANE + carboplatin developed any grade peripheral neuropathy compared with 64% of patients in the paclitaxel + carboplatin arm
Grade 3 peripheral neuropathy in the ABRAXANE + carboplatin arm vs paclitaxel + carboplatin
Grade 3 peripheral neuropathy in the ABRAXANE + carboplatin arm vs paclitaxel + carboplatin

Grade 3 neuropathy in the ABRAXANE + carboplatin arm vs the paclitaxel + carboplatin arm in Advanced NSCLC - chartnon-small cell lung cancer neuropathy

  • 1% of patients discontinued ABRAXANE due to peripheral neuropathy
  • No patients in the ABRAXANE + carboplatin arm developed Grade 4 peripheral neuropathy

YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL